Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $9.00 USD
Change Today +4.00 / 80.00%
Volume 4.0K
CSBR On Other Exchanges
As of 9:30 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

champions oncology inc (CSBR) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/25/15 - $10.08
52 Week Low
03/2/15 - $2.40
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

champions oncology inc (CSBR) Related Bloomberg News

View More Bloomberg News

champions oncology inc (CSBR) Related Businessweek News

No Related Businessweek News Found

champions oncology inc (CSBR) Details

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assists physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers POS products, including personalized tumor boards that are designed to provide access to oncologists with expertise in particular tumor types; and gene sequencing that analyzes the genetic makeup of patient’s tumor for the purpose of identifying useful drugs. In addition, the company offers Translational Oncology Solutions (TOS), including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies that uses vivo studies, which rely on implanting multiple tumors from TumorBank in mice and testing the therapy of interest on tumors. Further, it provides a bank of tumors that are acquired, collected, processed, validated, and stored for the use in TOS. The company markets its products through Internet, word of mouth, and a network of sales force. It serves patients, physicians, and drug development companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011 to reflect its new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology, Inc. is headquartered in Hackensack, New Jersey.

71 Employees
Last Reported Date: 07/29/15

champions oncology inc (CSBR) Top Compensated Officers

Chief Executive Officer, Secretary and Direct...
Total Annual Compensation: $53.2K
President and Director
Total Annual Compensation: $43.5K
Compensation as of Fiscal Year 2014.

champions oncology inc (CSBR) Key Developments

Champions Oncology, Inc.(NasdaqCM:CSBR) added to NASDAQ Composite Index

Champions Oncology, Inc. has been added to Nasdaq Composite Index.

Champions Oncology, Inc. will Change its Ticker to CSBRD from CSBR

Effective August 10, 2015, Champions Oncology, Inc. will change its Pink Sheets LLC stock ticker symbol to CSBRD from CSBR.

Champions Oncology, Inc. Announces Executive Changes

Champions Oncology, Inc. announced that David DeOrnellis joined the organization as global director of laboratory operations; Mark Weinstein assumed the role of chief information officer; and Jordan Rubinson was named chief commercial officer. David DeOrnellis joins Champions after 17 years of experience in biomedical research, laboratory management and leadership, holding such positions as Associate Director of LAS Technical Services at Novartis and Global Director of Quality Assurance at Harlan Laboratories. He will oversee all laboratory and implantation sites as the company increases capacity to accommodate sustained growth and high quality. Serving as the Company's CIO, Mark Weinstein will leverage his 25 years of experience as an IT professional in the healthcare, legal, and investment industries. Having served as Senior Technical Manager, Global Capital Markets for Bank of America, and Vice President of IT/CTO at Charles River Ventures, among other positions, Mark turned his focus to IT strategy and development for the biotechnology sector. His role at Champions includes developing and executing the Company's technology roadmap, and maximizing technology performance and impact. Mr. Rubinson has been with Champions for more than four years and previously held the role of Executive Vice President and General Manager for Personalized Oncology Services. His new role includes responsibility for all of the company's commercial strategy and development. Jordan has 17 years' experience in the pharmaceutical industry with Pfizer, GlaxoSmithKline, Aventis and most recently as the CEO of Polyheal Ltd., which is strategically allied with Teva Pharmaceuticals. Immediately prior, Mr. Rubinson worked at Pfizer as the marketing director in Israel.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CSBR:US $9.00 USD +4.00

CSBR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CSBR.
View Industry Companies

Industry Analysis


Industry Average

Valuation CSBR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.1x
Price/Book 5.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHAMPIONS ONCOLOGY INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at